Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. CCH:LN
3. META
4. CCHGY
5. PRY:IM
6. PRYMY
7. SPY
8. SKA-B
9. PBA
10. ALAR

Go back to Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Celldex (CLDX) Tops Q1 EPS by 3c

May 5, 2025 4:26 PM EDT

Celldex (NASDAQ: CLDX) reported Q1 EPS of ($0.71), $0.03 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $1.18 million versus the consensus estimate of $1.42 million.

For earnings history and earnings-related data on Celldex (CLDX) click here.

... More